Loading…
Remus Pharmaceuticals (REMUS)₹820.50+0.67%Pharmaceuticals
At the end of the Mar 2026 quarter, Remus Pharmaceuticals' shareholders were: promoters 70.92%, FIIs 5.24%, DIIs 0.83%, public 23.01%. Promoter holding is up 0.04 percentage points from 70.88% a quarter earlier. FII holding is up 2.26 percentage points from 2.98% a year earlier. 0.00% of promoter shares were pledged. It had 2,010 shareholders.
As of · Company filings (shareholding pattern)
| Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Promoters | 69.58% | 70.57% | 70.63% | 70.81% | 70.82% | 70.88% | 70.92% |
| FIIs | 2.36% | 3.22% | 2.98% | 3.13% | 4.73% | 4.98% | 5.24% |
| DIIs | 0.71% | 0.67% | 0.73% | 0.77% | 0.77% | 0.77% | 0.83% |
| Public | 27.35% | 25.54% | 25.66% | 25.29% | 23.68% | 23.37% | 23.01% |
| Promoter shares pledged | — | — | — | — | — | — | 0.00% |
| Number of shareholders | 857 | 1,125 | 1,578 | 1,754 | 1,879 | 2,033 | 2,010 |
| Holder | Category | Mar 2026 | Change (pp) |
|---|---|---|---|
| Shah Arpit Deepakkumar | Promoter | 17.63% | — |
| Roma Vinodbhai Shah | Promoter | 17.25% | — |
| Anar Swapnil Shah | Promoter | 16.95% | — |
| Swapnil Jatinbhai Shah | Promoter | 16.93% | — |
| India Emerging Giants Fund Limited | FII | 4.88% | — |
| Rekha Gunavanth Kumar | Public | 1.10% | — |
| Hemant Ishwarlal Modi | Promoter | 0.99% | — |
| Renosen Pharmaceuticals Private Limited | Promoter | 0.91% | — |
| Independent Director or his relatives | Public | 0.14% | — |
| Mansi Aadarsh Shah | Promoter | 0.07% | — |
| Sonal Hemantbhai Modi | Promoter | 0.07% | — |
| Vinodkumar Gandalal Shah | Promoter | 0.06% | — |
| Alkaben Dipakkumar Shah | Promoter | 0.02% | — |
| Key Managerial Personnel | Public | 0.01% | — |
| Dhruvalben Vishal Shah | Promoter | 0.01% | — |
Promoters held 70.92% of Remus Pharmaceuticals at the end of the Mar 2026 quarter, up 0.29 percentage points from 70.63% a year earlier.
In the Mar 2026 quarter, foreign institutional investors (FIIs) held 5.24% (up 0.26 percentage points from 4.98% a quarter earlier) and domestic institutions (DIIs) held 0.83% (up 0.06 percentage points from 0.77% a quarter earlier).
No. The Mar 2026 filing shows no pledged promoter shares.
Remus Pharmaceuticals had 2,010 shareholders at the end of the Mar 2026 quarter, against 1,578 a year earlier.
India Emerging Giants Fund Limited (FII) held 4.88% at the end of the Mar 2026 quarter, the largest named holding outside the promoter group.